BR112015022692A2 - método para a preparação de ticagrelor, e, composto - Google Patents
método para a preparação de ticagrelor, e, compostoInfo
- Publication number
- BR112015022692A2 BR112015022692A2 BR112015022692A BR112015022692A BR112015022692A2 BR 112015022692 A2 BR112015022692 A2 BR 112015022692A2 BR 112015022692 A BR112015022692 A BR 112015022692A BR 112015022692 A BR112015022692 A BR 112015022692A BR 112015022692 A2 BR112015022692 A2 BR 112015022692A2
- Authority
- BR
- Brazil
- Prior art keywords
- ticagrelor
- preparation
- compound
- pyrimidine
- formula
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 3
- OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 title abstract 3
- 229960002528 ticagrelor Drugs 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 2
- 238000006243 chemical reaction Methods 0.000 abstract 2
- 125000006239 protecting group Chemical group 0.000 abstract 2
- FMZMAGZGEIFGFD-UHFFFAOYSA-N 2-aminocyclopentane-1,1-diol Chemical compound NC1CCCC1(O)O FMZMAGZGEIFGFD-UHFFFAOYSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000009833 condensation Methods 0.000 abstract 1
- 230000005494 condensation Effects 0.000 abstract 1
- 238000010511 deprotection reaction Methods 0.000 abstract 1
- 150000002009 diols Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ2013-189A CZ307217B6 (cs) | 2013-03-14 | 2013-03-14 | Zlepšený způsob výroby a nové intermediáty syntézy ticagreloru |
| PCT/CZ2014/000028 WO2014139489A1 (en) | 2013-03-14 | 2014-03-14 | Method for the preparation of ticagrelor and intermediates suitable therefore |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015022692A2 true BR112015022692A2 (pt) | 2017-07-18 |
Family
ID=50478119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015022692A BR112015022692A2 (pt) | 2013-03-14 | 2014-03-14 | método para a preparação de ticagrelor, e, composto |
Country Status (3)
| Country | Link |
|---|---|
| BR (1) | BR112015022692A2 (cs) |
| CZ (1) | CZ307217B6 (cs) |
| WO (1) | WO2014139489A1 (cs) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ2013866A3 (cs) * | 2013-11-08 | 2015-05-20 | Zentiva, K.S. | Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru |
| CN109400613B (zh) * | 2015-12-31 | 2021-05-07 | 上海医药集团股份有限公司 | 喹啉类化合物富马酸盐的晶型、制备方法、组合物与应用 |
| CN115160320B (zh) * | 2022-06-27 | 2024-05-07 | 南通常佑药业科技有限公司 | 一种手性嘧啶并三唑类替格瑞洛的制备方法 |
| CN119080782A (zh) * | 2024-10-10 | 2024-12-06 | 重庆普佑生物医药有限公司 | 替卡格雷的合成方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI229674B (en) | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
| GB0013488D0 (en) | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Chemical compound |
| GB0013407D0 (en) | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Forms of a chemical compound |
| CN102311437A (zh) * | 2010-07-01 | 2012-01-11 | 北京迈劲医药科技有限公司 | 一种抗血小板凝集药替卡格雷的制备方法 |
| EP2694514A2 (en) * | 2011-04-06 | 2014-02-12 | Teva Pharmaceutical Industries Ltd. | New intermediates and processes for preparing ticagrelor |
| EP2607355A1 (en) * | 2011-12-23 | 2013-06-26 | LEK Pharmaceuticals d.d. | Synthesis of triazolopyrimidine compounds |
| CN104114542B (zh) * | 2011-12-23 | 2017-11-14 | 力奇制药公司 | 三唑并嘧啶化合物的合成 |
-
2013
- 2013-03-14 CZ CZ2013-189A patent/CZ307217B6/cs not_active IP Right Cessation
-
2014
- 2014-03-14 WO PCT/CZ2014/000028 patent/WO2014139489A1/en active Application Filing
- 2014-03-14 BR BR112015022692A patent/BR112015022692A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CZ2013189A3 (cs) | 2014-09-24 |
| WO2014139489A1 (en) | 2014-09-18 |
| CZ307217B6 (cs) | 2018-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013000077A1 (es) | Uso de compuestos derivados de ribosas 1’ sustituidas que comprenden nucleobases de pirrolo[1,2-f][1,2,4]triazina para tratar infecciones por paramyxoviridae; compuestos derivados de ribosas 1’ sustituidas que comprenden nucleobases de pirrolo[1,2-f][1,2,4]triazina; y composicion farmaceutica que los comprende. | |
| CR20130247A (es) | Compuestos tricíclicos de la pi3k y métodos de uso | |
| CL2008002397A1 (es) | Compuestos derivados de imidazoles biciclicos fusionados; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar neoplasia benigna o maligna. | |
| DOP2015000227A (es) | Virus de la enfermedad de newcastle y usos de los mismos | |
| BR112013018402A2 (pt) | sistema de bio-refinaria, componentes para o mesmo, processos de uso, e produtos derivados do mesmo | |
| CL2008002319A1 (es) | Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer. | |
| BR112016002101A2 (pt) | propante, e, métodos de fabricação e formação de um propante | |
| IN2014DN10274A (cs) | ||
| CO7240372A2 (es) | Formulaciones farmacéuticas tópicas no acuosas | |
| BR112015025709A2 (pt) | monoterapia com gla para uso em tratamento de câncer | |
| BR112015022692A2 (pt) | método para a preparação de ticagrelor, e, composto | |
| BR112014003273A8 (pt) | espessantes associativos com base nos polímeros hiper-ramificados | |
| BR112012023660A2 (pt) | novos métodos para direcionar células-tronco cancerosas | |
| BR112015029307A2 (pt) | substrato para crescimento de planta, e, uso de um substrato para crescimento de planta | |
| BR112015014438A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112018000187A2 (pt) | composto, composição, método, e, uso de um composto ou composição | |
| MX350828B (es) | Uso de ligandos sigma en la hiperalgesica inducida por opioides. | |
| BR112015026388A2 (pt) | métodos e composições para cicatrização de feridas | |
| BRPI1008382A8 (pt) | Extrato de oregano para vivacidade | |
| BR112015023493A2 (pt) | método para tratamento de um tumor, método para identificar um sujeito, método para a seleção de um tratamento, e, kit | |
| BR112017024609A2 (pt) | sistemas, métodos, e dispositivos para compartilhamento e coincidência de informações | |
| BR112014011481A2 (pt) | hidrolisado de colágeno e seu uso | |
| BR112016007062A2 (pt) | variantes de protoxina-ii e métodos de uso | |
| BR112014029874A8 (pt) | composição farmacêutica do tipo emulsão óleo em água, composições e uso da composição farmacêutica | |
| CL2015002191A1 (es) | Composición antifúngica tópica para el tratamiento de onicomicosis. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2505 DE 08-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |